AAIC 2025 Abstract
Use of Lecanemab for Alzheimer's Disease within the Veteran's Health Foundation: Early Findings
Study in peopleInterventions
Abstract
Background: Lecanemab, an anti‐amyloid monoclonal antibody for Alzheimer's disease, was approved for use in the Veteran's Health Administration (VHA) in 2023. Little is known about the real‐world use and outcomes of lecanemab.
